Literature DB >> 20962560

[Usefulness of lactulose breath test for the prediction of small intestinal bacterial overgrowth in irritable bowel syndrome].

Jung Soo Park1, Jung Hwan Yu, Hyun Chul Lim, Jie Hyun Kim, Young Hoon Yoon, Hyo Jin Park, Sang In Lee.   

Abstract

BACKGROUND/AIMS: Lactulose breath test (LBT) has been used as a presumptive surrogate marker for small intestinal bacterial overgrowth (SIBO). However, recent reports suggest that abnormal LBT cannot discriminate patients with irritable bowel syndrome (IBS) from the control. Thus, the aim of this study was to evaluate the usefulness of LBT in IBS.
METHODS: LBT from 76 IBS patients, 70 functional bowel disorders (FBD), and 40 controls were examined. LBT was considered positive if (1) baseline breath hydrogen (H₂) >20 parts per million (ppm) or rise of breath H₂ >20 ppm above the baseline in <90 mins, or (2) baseline breath methane (CH₄) >10 ppm or rise of breath CH₄ >10 ppm above the baseline in <90 mins. The subjects were categorized into predominant hydrogen producers (PHP), predominant methane producers (PMP), combined producer, and both negative group based on LBT.
RESULTS: The rate of abnormal LBT in the IBS, FBD, and control group were 44.7%, 41.4%, and 40.0% respectively without significant differences. The rate of PHP or PMP was not significantly different among the IBS, FBD, and control group. When clinical characteristics were analyzed in IBS and FBD according to LBT types, IBS subtypes and symptoms were not significantly different.
CONCLUSIONS: LBT was not useful to discriminate IBS/FBD patients from the control. The assessment of SIBO by LBT in IBS should be revalidated in the future.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20962560     DOI: 10.4166/kjg.2010.56.4.242

Source DB:  PubMed          Journal:  Korean J Gastroenterol        ISSN: 1598-9992


  14 in total

Review 1.  Gastroduodenal "Dysbiosis": a New Clinical Entity.

Authors:  Ayesha Shah; Mark Morrison; Gerald J Holtmann
Journal:  Curr Treat Options Gastroenterol       Date:  2018-12

Review 2.  Post-infectious IBS, tropical sprue and small intestinal bacterial overgrowth: the missing link.

Authors:  Uday C Ghoshal; Kok-Ann Gwee
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-05-17       Impact factor: 46.802

3.  Prevalence and predictors of small intestinal bacterial overgrowth in irritable bowel syndrome: a systematic review and meta-analysis.

Authors:  Binrui Chen; John Jae-Woo Kim; Yawen Zhang; Lijun Du; Ning Dai
Journal:  J Gastroenterol       Date:  2018-05-14       Impact factor: 7.527

Review 4.  Irritable bowel syndrome and small intestinal bacterial overgrowth: meaningful association or unnecessary hype.

Authors:  Uday C Ghoshal; Deepakshi Srivastava
Journal:  World J Gastroenterol       Date:  2014-03-14       Impact factor: 5.742

Review 5.  Breath tests and irritable bowel syndrome.

Authors:  Satya Vati Rana; Aastha Malik
Journal:  World J Gastroenterol       Date:  2014-06-28       Impact factor: 5.742

6.  Methane positive small intestinal bacterial overgrowth in inflammatory bowel disease and irritable bowel syndrome: A systematic review and meta-analysis.

Authors:  Arjun Gandhi; Ayesha Shah; Michael P Jones; Natasha Koloski; Nicholas J Talley; Mark Morrison; Gerald Holtmann
Journal:  Gut Microbes       Date:  2021 Jan-Dec

7.  Is the intestinal gas associated with the development of right colonic diverticula?: author's reply.

Authors:  Sung-Ill Jang; Hyojin Park
Journal:  J Neurogastroenterol Motil       Date:  2011-04-27       Impact factor: 4.924

8.  Small bowel bacterial overgrowth in patients with irritable bowel syndrome: the first study in iran.

Authors:  Mehdi HayatBakhsh Abbasi; MohammadJavad Zahedi; Sodaif Darvish Moghadam; Sara Shafieipour; Mahroo HayatBakhsh Abbasi
Journal:  Middle East J Dig Dis       Date:  2015-01

9.  The gut microbiota and irritable bowel syndrome: friend or foe?

Authors:  Uday C Ghoshal; Ratnakar Shukla; Ujjala Ghoshal; Kok-Ann Gwee; Siew C Ng; Eamonn M M Quigley
Journal:  Int J Inflam       Date:  2012-04-22

10.  Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowth.

Authors:  Victor Chedid; Sameer Dhalla; John O Clarke; Bani Chander Roland; Kerry B Dunbar; Joyce Koh; Edmundo Justino; Eric Tomakin; Gerard E Mullin
Journal:  Glob Adv Health Med       Date:  2014-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.